---
title: 'Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin
  in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study'
date: '2024-05-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38691295/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240501181354&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: In line with the results of the TOPAZ-1 trial, adding durvalumab
  to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms
  of OS and PFS in a real-world setting of patients with advanced ...'
disable_comments: true
---
CONCLUSION: In line with the results of the TOPAZ-1 trial, adding durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of OS and PFS in a real-world setting of patients with advanced ...